Kenneth S. Mantel

Changes to Board Composition

• Elliott Management
• Catalent (settlement reached for four board seats)
• Goodyear (settlement reached for three board seats)
• Constellation Brands (settlement reached for two board seats)
• Pinterest (settlement reached for one board seat)
• Cardinal Health (settlement reached for four board seats)
• Suncor Energy (settlement reached for three board seats)
• Duke Energy (settlement reached for two board seats)
• Principal Financial Group, Inc. (settlement reached for two board seats)
• Public Storage (settlement reached for two board seats)
• Alkermes (settlement reached for one board seat)
• Nielsen Holdings plc (settlement reached for one board seat)
• Twitter, Inc. (settlement reached for one board seat)
• Evergy, Inc. (settlement reached for two board seats)
• Peabody Energy Corporation (settlement reached for three board seats)
• QEP Resources, Inc. (agreement to select two mutually agreeable directors)
• Sempra Energy (agreement to appoint two mutually agreed independent directors)
• Commvault Systems, Inc. (settlement reached for two board seats)
• QEP Resources, Inc. (agreement to announce strategic initiatives and present board declassification proposal to stockholders)
• Alexion Pharmaceuticals, Inc. (agreement to appoint a mutually agreeable director)
• Arconic Inc. (settlement reached to nominate three directors at the annual meeting; all three elected by shareholders)
• CDK Global, Inc. (settlement reached for two independent directors identified by Elliott)
• American Capital (entry into agreements to support acquisition by Ares Capital)
• Sherborne Investors (settlement reached for appointment of fund principal to board)

• Starboard Value
• Forest City Realty Trust, Inc. (settlement reached for five board seats)
• Cars.com Inc. (settlement reached for three board seats)
• Tessera Technologies (settlement reached to nominate six directors at the Annual Meeting; all 6 elected by shareholders)
• DSP Group (settlement reached to add two independent directors to board)

• Daniel A. Ninivaggi (Protean Services LLC) at Tenneco Inc. (settlement reached for one board seat)
• Broadfin Capital at BioDelivery Sciences International, Inc. (agreements reached for three board seats and for equity financing led by Broadfin)
• City of London Investment Management Company at China Fund, Inc. (agreement to search for a new investment manager and form a committee with the City of London to resolve outstanding matters)
• Land & Buildings at QTS Realty Trust Inc. (withhold campaign against two directors)
• Snow Park Capital at Monogram Residential Trust, Inc. (settlement reached for an observer to the board)

Corporate Matters

Mergers & Acquisitions

• Represented Alleghany Corporation, a multinational holding company with a core position in property and casualty reinsurance and insurance, in a series of acquisitions of controlling interests in privately held companies.
• Represented Remark Holdings, Inc., a technology company, in a series of acquisitions in the digital media space.
• Represented Novation Companies, Inc. in its acquisition of a healthcare staffing company as part of its Chapter 11 reorganization process.
• Represented Landry’s, Inc. in its acquisition of B.R. Guest Holdings
• Represented Ness Technologies, Inc., a global provider of information technology solutions and services, in its merger with an affiliate of a private equity investment fund.
• Represented New Century Equity Holdings Corp. in its acquisition of a fashion model management company and affiliated entities.

Financings

• Represented Alleghany Corporation in public offerings of senior notes and in equity and debt financings for portfolio companies.
• Represented Remark Holdings, Inc. in numerous equity and debt financings, including private placements, public offerings, equity lines, and credit facilities.
• Represented GAMCO Investors in equity and debt self-tender offers.
• Represented CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of cardiorenal disease, in its initial public offering.